Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteomics analyses by iMPAQT in sunitinib resistant cells and its HIF2a knock out cells

ABSTRACT: This analysis was performed among 786-o renal cell carcinoma cell line, its sunitinib resistant cell, and sunitinib resistant Hif2a knock out cell.

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Hirofumi Yoshino

PROVIDER: PXD007222 | JPOST Repository | Wed Aug 09 00:00:00 BST 2017

REPOSITORIES: jPOST

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	1-cellmix-1.wiff	Wiff
	1-cellmix-1.wiff.scan	Wiff
	2-786-o-test.wiff	Wiff
	2-786-o-test.wiff.scan	Wiff
	3-786-o-rediSni.wiff	Wiff

Items per page:

1 - 5 of 9

Similar Datasets

E-GEOD-51627

Project description:Treatment of renal cell carcinoma cell line A-498 with zebularine

2025-01-24 | E-GEOD-51627 | ExpressionAtlas

E-MEXP-1509

Project description:RNAi knock down of mSin3a-b and SBTB4 in human colon carcinoma cell line HCT116

2025-01-22 | E-MEXP-1509 | ExpressionAtlas

E-MTAB-7808

Project description:RNA-seq upon PAX8 knockdown in Renal Cell Carcinoma cell lines

2025-01-23 | E-MTAB-7808 | ExpressionAtlas

E-GEOD-46699

Project description:Smoking and Obesity Related Molecular Alterations in Clear Cell Renal Cell Carcinoma

2025-01-24 | E-GEOD-46699 | ExpressionAtlas

E-GEOD-12606

Project description:HLA ligand profiles of primary renal cell carcinoma maintained in metastases.sue

2025-01-24 | E-GEOD-12606 | ExpressionAtlas

Increased HRD score in cisplatin resistant penile cancer cells

Project description:HRD Score was generated from a penile carcinoma cell line resistant to 5FU and CDDP as well as cross resistant cell line.

2023-11-17 | GSE218782 | GEO

E-GEOD-53757

Project description:Gene array analysis of clear cell renal cell carcinoma tissue versus matched normal kidney tissue

2025-01-24 | E-GEOD-53757 | ExpressionAtlas

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)

Project description:This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in participants with selected tumor indications. New recruitment is open for all active cohorts. Active cohorts: Escalation revised dosing regimen cohort. Closed cohorts: Non-small cell lung cancer (NSCLC, first line), NSCLC (post-platinum), metastatic breast cancer (MBC), colorectal cancer (CRC), urothelial carcinoma (secondary), mesothelioma, gastric/GEJ cancer (first line switch maintenance and second line), and ovarian cancer (secondary and platinum refractory + liposomal doxorubicin), renal cell carcinoma (second line) melanoma and head, neck squamous cell carcinoma (HNSCC), castrate-resistant prostate cancer (CRPC), adrenocortical carcinoma (ACC) urothelial carcinoma (efficacy), gastric/gastroesophageal junction (GEJ) cancer (third line), renal cell carcinoma (RCC, first line) and escalation phase .

| 2138571 | ecrin-mdr-crc

Nonclinical in-vitro evaluation of the transcriptomic and metabolic effects of immune checkpoint inhibitors on sunitinib-resistant renal cell carcinoma

Project description:Recently, immune checkpoint inhibitors (ICIs) have been approved as first line and second-line therapies for individuals with advanced renal cell carcinoma (RCC) who developed a resistance to anti-angiogenic therapies. It remains unknown how ICIs efficacy is affected by the development of resistance to anti-angiogenic inhibitors. Thus, our goal is to evaluate transcriptomic and metabolic effects after ICI therapy of sunitinib-resistant RCC and compare the efficacy of ICIs between naïve and sunitinib-resistant RCC.

2025-01-01 | GSE216495 | GEO

E-MTAB-7085

Project description:mRNA profile of HeLaS3 cell line and AGO2 Knock-Out HeLaS3 subclone

2025-01-23 | E-MTAB-7085 | ExpressionAtlas